^
Association details:
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
Source:
Title:

COMPARISON OF CHIDAMIDE-CONTAINED TREATMENT MODALITIES VERSUS CHEMOTHERAPY IN RELAPSED OR REFRACTORY PERIPHERAL T-CELL LYMPHOMA

Published date:
05/12/2021
Excerpt:
In the subgroup of CD30(-) patients, PFS was superior in the Chidamide+ChT group as compared with other groups (p =0.002, Figure 5)….first retreatment with chidamide+ChT regimen showed more PFS benefit than ChT and targeted therapy for RR PTCL patients, especially those with high second-line IPI, younger than 60 years and CD30(-).
Secondary therapy:
Chemotherapy